Effects of mosapride on esophageal functions and gastroesophageal reflux

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 6, 2010, Pages 1066-1071

  Koshino, Kenji ^a   Adachi, Kyoichi ^a   Furuta, Kenji ^a   Ohara, Shunji ^a   Morita, Terumi ^a   Nakata, Shuji ^a   Tanimura, Takashi ^a   Miki, Masaharu ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Esophageal peristaltic contraction; Gastroesophageal reflux; Impedance monitoring; Lower esophageal sphincter; Saliva

Indexed keywords

MOSAPRIDE CITRATE; MOSAPRIDE; ANTIULCER AGENT; BENZAMIDE DERIVATIVE; MORPHOLINE DERIVATIVE; SEROTONIN AGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DRUG ACTIVITY; ESOPHAGUS FUNCTION; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; MOTOR ACTIVITY; PH MEASUREMENT; PRIORITY JOURNAL; SALIVATION; CROSSOVER PROCEDURE; DRUG EFFECT; HUMAN EXPERIMENT; JAPAN; NORMAL HUMAN; POSTPRANDIAL STATE; STOMACH ACID SECRETION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ESOPHAGEAL PH MONITORING; ESOPHAGUS; FOLLOW UP; IMPEDANCE; LOWER ESOPHAGUS SPHINCTER; MANOMETRY; METABOLISM; PATHOPHYSIOLOGY; PERISTALSIS; PHYSIOLOGY; PRESSURE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SALIVA; SECRETION (PROCESS);

ADULT; ANTI-ULCER AGENTS; BENZAMIDES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC IMPEDANCE; ESOPHAGEAL PH MONITORING; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGUS; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MANOMETRY; MORPHOLINES; PERISTALSIS; PRESSURE; PROGNOSIS; REFERENCE VALUES; SALIVA; SEROTONIN RECEPTOR AGONISTS;

EID: 77952985484     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06280.x     Document Type: Article

References (36)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 2006 101 : 1900 1920.
2. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 1999 94 : 1434 1442.
3. Castell DO, Mainie I, Tutuian R. Non-acid gastroesophageal reflux: documenting its relationship to symptoms using multichannel intraluminal impedance (MII). Trans. Am. Clin. Climatol. Assoc. 2005 116 : 321 333.
4. Miwa H, Sasaki M, Furuta T et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment. Pharmacol. Ther. 2007 26 : 69 77.
5. Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 2003 15 : 1115 1121. (Pubitemid 37267228)
6. Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J. Gastroenterol. Hepatol. 2008 23 : 746 751.
7. Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Strategy for treatment of nonerosive reflux disease in Asia. World J. Gastroenterol. 2008 14 : 3123 3128.
8. Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008 68 : 981 991.
9. Kinoshita Y, Hashimoto T, Kawamura A et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment. Pharmacol. Ther. 2005 21 : 37 41.
10. Otaka M, Jin M, Odashima M et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment. Pharmacol. Ther. 2005 21 : 42 6.
11. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment. Pharmacol. Ther. 2005 21 : 32 6.
12. Adachi K, Ono M, Kawamura A, Yuki M, Fujishiro H, Kinoshita Y. Nizatidine and cisapride enhance salivary secretion in humans. Aliment. Pharmacol. Ther. 2002 16 : 297 301.
13. Fox MR, Bredenoord AJ. Oesophageal high-resolution manometry: moving from research into clinical practice. Gut 2008 57 : 405 423.
14. Salvador R, Dubecz A, Polomsky M et al. A new era in esophageal diagnostics: the image-based paradigm of high-resolution manometry. J. Am. Coll. Surg. 2009 208 : 1035 1044.
15. Clouse RE, Staiano A. Topography of the esophageal peristaltic pressure wave. Am. J. Physiol. 1991 261 : 677 684.
16. Clouse RE, Staiano A. Topography of normal and high-amplitude esophageal peristalsis. Am. J. Physiol. 1993 265 : 1098 1107.
17. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001 120 : 1599 1606.
18. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004 53 : 1024 1131.
19. Iwakiri K, Sugiura T, Kotoyori M et al. Effect of body position on lower esophageal sphincter pressure. J. Gastroenterol. 1999 34 : 305 309.
20. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr. Gastroenterol. Rep. 2008 10 : 252 257.
21. Furuichi A, Makimoto N, Ogishima M et al. In vivo microdialysis assessment of nerve-stimulated contractions associated with increased acetylcholine release in the dog intestine. Jpn. J. Pharmacol. 1999 79 : 109 112.
22. Makimoto N, Sakurai-Yamashita Y, Furuichi A et al. In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytriptamine. Jpn. J. Pharmacol. 2002 90 : 28 35.
23. Staiano A, Clouse RE. The effects of cisapride on the topography of oesophageal peristalsis. Aliment. Pharmacol. Ther. 1996 10 : 875 882.
24. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994 47 : 116 152.
25. Adachi K, Furuta K, Katsube T et al. Nizatidine and cisapride increase salivary secretion in rats. Dig. Dis. Sci. 2004 49 : 399 403.
26. Goldin GF, Marcinkiewicz M, Zbroch T, Bityutskiy LP, McCallum RW, Sarosiek J. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease. Dig. Dis. Sci. 1997 42 : 1362 1369.
27. Cataldo FM. Cisapride and risk of cardiac complications. Minerva Pediatr. 1999 51 : 309 311.
28. Iwanaga Y, Miyashita N, Mizutani F et al. Stimulatory effect of N-[4-[2-(dimethylamino)-ethoxy] benzyl]-3,4-dimethoxybenzamide hydrochloride (HSR-803) on normal and delayed gastrointestinal propulsion. Jpn. J. Pharmacol. 1991 56 : 261 269.
29. Choi MG, Choo KY, Kim BW et al. The effect of itopride on proximal gastric tone and visceral perception in healthy human. Korean J Gastroenterol. 2000 36 : 293 301. 28.
30. Kim YS, Kim TH, Choi CS et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J. Gastroenterol. 2005 11 : 4210 4214.
31. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure ingastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2000 14 : 1503 1509.
32. Degen L, Matzinger D, Merz M et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther. 2001 15 : 1745 1751.
33. Tutuian R, Mainie I, Allan R et al. Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment. Pharmacol. Ther. 2006 24 : 155 162.
34. Katoh T, Saitoh H, Ohno N et al. Drug interaction between mosapride and erythromycin without electrocardiographic changes. Jpn. Heart J. 2003 44 : 225 234.
35. Mizuta Y, Shikuwa S, Isomoto H et al. Recent insights into digestive motility in functional dyspepsia. J. Gastroenterol. 2006 41 : 1025 1040.
36. Ruth M, Hamelin B, Röhss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 1998 12 : 35 40.